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Editorial
Traumatic brain injury (TBI), whatever its cause, is already 
associated usually with disability and death worldwide.[1] The 
mechanism of injury in TBI includes primary and secondary 
injuries. The primary brain injury usually appears just when 
the trauma is occurred. Common mechanisms comprise direct 
impact, rapid acceleration/deceleration, penetrating injury, and 
shock waves. The damage that results include a combination 
of focal contusions and hematomas, as well as shearing of 
white matter tracts (diffuse axonal injury) along with cerebral 
edema and swelling.[2] While effective in managing the primary 
injury to the brain and the skull, these treatment modalities 
do not address the complex secondary cascades that occur at 
a cellular level following initial injury and greatly affect the 
ultimate neurologic outcome.[3] Neuroprotective agents that 
can limit the secondary tissue loss and/or improve behavioral 
outcomes have been identified in multiple animal models of 
acute brain injury. However, translation to the clinical setting 
has been largely disappointing.[4] More than 20 neuroprotective 
agents have been examined in experimental studies during 
the last 30 years[5] without evidence of significant outcome 
enhancement.[6] Some existing therapeutic interventions for 
neuroprotection are reperfusion strategies in ischemic stroke, 
prevention of secondary insults after TBI by, for example, 
decompressive craniectomy, maintaining optimal cerebral 
perfusion pressure, management of anemia in TBI cases, 
preserving brain perfusion in sepsis, and induced hypothermia. 
In recent years, some novel therapeutics have been introduced 
as neuroprotectors including infusion of mesenchymal stromal 
cells, remote ischemic conditioning (brief repeated cycles of 
peripheral vascular occlusion and deocclusion), the use of 
volatile anesthetic agents, metabolic therapy (i.e., sodium 
lactate infusion), sex hormones, for example, intravenous 
progesterone, and hyperoxia.[4] Nevertheless, to date, no 
neuroprotective agents or strategies have been shown to 
produce improved outcome significantly.
Among therapeutics being investigated, magnesium, 
cyclosporine, statins, and erythropoietin might have 
neurocytoprotective effects. Although during a large 
multicenter study on 606 patients with a TBI neurologic 
outcome at 6 months was not improved, mortality was 
nonsignificantly lower (11% vs. 16%) in patients who received 
erythropoietin.[7] Despite all the disappointments, there is 
still some hope. It will be achievable by a hybrid package 
of clinical measures including ensuring adequate oxygen 
delivery and avoiding excessive oxygen consumption[4] 
using advanced neuromonitoring such as jugular venous 
oximetry, brain tissue oxygen tension monitoring, cerebral 
microdialysis, and thermal diffusion flowmetry[2] along with 
some therapeutic measures, and prevention and limitation 
of secondary insults in the early phases after the injury. We 
hope successes in the promising neuroprotective modalities 
in the future.
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